GlassScriptPhysician profile
Gregory Scott Ward
NPI 1609405505
$806.52
in general payments reported to CMS, 2019-2025
9 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.82 · 2023: $83.64 · 2024: $276 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $194.80 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $165.81 | 2024-2025 | Lifevest |
| Novo Nordisk INC | $131.25 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $112.09 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $97.62 | 2024-2025 | Camzyos |
| Esperion Therapeutics, INC. | $38.82 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $27.93 | 2024 | Uptravi, Opsumit |
| Kiniksa Pharmaceuticals International, Plc | $22.01 | 2024 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $16.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.